These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

597 related articles for article (PubMed ID: 11806463)

  • 1. GLP-1 effect upon the GPI/IPG system in adipocytes and hepatocytes from diabetic rats.
    Márquez L; González N; Puente J; Valverde L; Villanueva-Peñacarrillo ML
    Diabetes Nutr Metab; 2001 Oct; 14(5):239-44. PubMed ID: 11806463
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inositolphosphoglycans possibly mediate the effects of glucagon-like peptide-1(7-36)amide on rat liver and adipose tissue.
    Márquez L; Trapote MA; Luque MA; Valverde I; Villanueva-Peñacarrillo ML
    Cell Biochem Funct; 1998 Mar; 16(1):51-6. PubMed ID: 9580153
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inositolphosphoglycans and diacyglycerol are possible mediators in the glycogenic effect of GLP-1(7-36)amide in BC3H-1 myocytes.
    Galera C; Clemente F; Alcantara A; Trapote MA; Perea A; Lopez-Delgado MI; Villanueva-Penacarrillo ML; Valverde I
    Cell Biochem Funct; 1996 Mar; 14(1):43-8. PubMed ID: 8907253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glucagon-like peptide 1 (GLP-1) in the treatment of diabetes.
    Nauck MA
    Horm Metab Res; 2004; 36(11-12):852-8. PubMed ID: 15655719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Glycaemic effects of incretins in Type 1 diabetes mellitus: a concise review, with emphasis on studies in humans.
    Dupre J
    Regul Pept; 2005 Jun; 128(2):149-57. PubMed ID: 15780434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversal of type 2 diabetes in mice by products of malaria parasites. II. Role of inositol phosphoglycans (IPGs).
    Elased KM; Gumaa KA; de Souza JB; Rahmoune H; Playfair JH; Rademacher TW
    Mol Genet Metab; 2001 Jul; 73(3):248-58. PubMed ID: 11461192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potentiation by methyl pyruvate of GLP-1 insulinotropic action in normal rats.
    Valverde I; Cancelas J; Villanueva-Peñacarrillo ML; Malaisse WJ
    Int J Mol Med; 2001 Jun; 7(6):621-3. PubMed ID: 11351275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective amplification of the late phase insulin response to glucose by GIP in obese Type II diabetic patients.
    Vilsbøll T; Krarup T; Madsbad S; Holst JJ
    Diabetologia; 2002 Aug; 45(8):1111-9. PubMed ID: 12189441
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of nutrient ingestion on glucagon-like peptide 1 (7-36 amide) secretion in human type 1 and type 2 diabetes.
    Lugari R; Dell'Anna C; Ugolotti D; Dei Cas A; Barilli AL; Zandomeneghi R; Marani B; Iotti M; Orlandini A; Gnudi A
    Horm Metab Res; 2000 Oct; 32(10):424-8. PubMed ID: 11069208
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glucagon-like peptide-1 and exendins on kinase activity, glucose transport and lipid metabolism in adipocytes from normal and type-2 diabetic rats.
    Sancho V; Trigo MV; González N; Valverde I; Malaisse WJ; Villanueva-Peñacarrillo ML
    J Mol Endocrinol; 2005 Aug; 35(1):27-38. PubMed ID: 16087719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Analogs of glucagon-like peptide-1 (GLP-1): an old concept as a new treatment of patients with diabetes mellitus type 2].
    Diamant M; Bunck MC; Heine RJ
    Ned Tijdschr Geneeskd; 2004 Sep; 148(39):1912-7. PubMed ID: 15495988
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic potential of glucagon-like peptide 1 in type 2 diabetes.
    Nauck M
    Diabet Med; 1996 Sep; 13(9 Suppl 5):S39-43. PubMed ID: 8894470
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of GLP-1 treatment on GLUT2 and GLUT4 expression in type 1 and type 2 rat diabetic models.
    Villanueva-Peñacarrillo ML; Puente J; Redondo A; Clemente F; Valverde I
    Endocrine; 2001 Jul; 15(2):241-8. PubMed ID: 11720253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Normalizing action of exendin-4 and GLP-1 in the glucose metabolism of extrapancreatic tissues in insulin-resistant and type 2 diabetic states.
    Moreno P; Nuche-Berenguer B; Gutiérrez-Rojas I; Acitores A; Sancho V; Valverde I; González N; Villanueva-Peñacarrillo ML
    J Mol Endocrinol; 2012 Feb; 48(1):37-47. PubMed ID: 22065862
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characteristics of GLP-1 and exendins action upon glucose transport and metabolism in type 2 diabetic rat skeletal muscle.
    Arnés L; González N; Tornero-Esteban P; Sancho V; Acitores A; Valverde I; Delgado E; Villanueva-Peñacarrillo ML
    Int J Mol Med; 2008 Jul; 22(1):127-32. PubMed ID: 18575785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S 23521, a new glucagon-like peptide 1 (GLP-1) analogue.
    Uçkaya G; Delagrange P; Chavanieu A; Grassy G; Berthault MF; Ktorza A; Cerasi E; Leibowitz G; Kaiser N
    J Endocrinol; 2005 Mar; 184(3):505-13. PubMed ID: 15749809
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.
    D'Alessio DA; Vahl TP
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E882-90. PubMed ID: 15140755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of an olive oil-enriched diet on glucagon-like peptide 1 release and intestinal content, plasma insulin concentration, glucose tolerance and pancreatic insulin content in an animal model of type 2 diabetes.
    Cancelas J; Prieto PG; Villanueva-Peñacarrillo ML; Valverde I; Malaisse WJ
    Horm Metab Res; 2006 Feb; 38(2):98-105. PubMed ID: 16523410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of glucagon-like peptide 1 on the kinetics of glycogen synthase a in hepatocytes from normal and diabetic rats.
    López-Delgado MI; Morales M; Villanueva-Peñacarrillo ML; Malaisse WJ; Valverde I
    Endocrinology; 1998 Jun; 139(6):2811-7. PubMed ID: 9607788
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The multifaceted potential of glucagon-like peptide-1 as a therapeutic agent.
    Lam NT; Kieffer TJ
    Minerva Endocrinol; 2002 Jun; 27(2):79-93. PubMed ID: 11961501
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.